(Total Views: 687)
Posted On: 01/31/2022 9:40:42 AM
Post# of 153965
NAFLD is where NASH starts but it doesn't necessarily progress to NASH. The difference between NAFLD and NASH is the level of fibrosis. In NAFLD fibrosis may just be starting to occur. If fibrosis continues hen you end up in one of the four levels of NASH.
The proper way to do it is to look at NASH vs. NASH which I outlined here -
https://investorshangout.com/post/view?id=6331942
I've previously said the 350mg results were good but not great but even those results seem to be more than a match for Madrigal. The problem for comparison is incomplete data from both companies.
The matchup is from Cytodyn's 14 week trial vs. Madrigal's 52 week data. Longer usage of leronlimab should skew the data better for leronlimab especially in MRI-PDFF.
Knowing that leronlimab has always shown better effect at the higher dose it would not surprise me to see a 10% to 15% better result from 700mg than from 350mg.
The proper way to do it is to look at NASH vs. NASH which I outlined here -
https://investorshangout.com/post/view?id=6331942
I've previously said the 350mg results were good but not great but even those results seem to be more than a match for Madrigal. The problem for comparison is incomplete data from both companies.
The matchup is from Cytodyn's 14 week trial vs. Madrigal's 52 week data. Longer usage of leronlimab should skew the data better for leronlimab especially in MRI-PDFF.
Knowing that leronlimab has always shown better effect at the higher dose it would not surprise me to see a 10% to 15% better result from 700mg than from 350mg.
(12)
(0)
